Last $0.26 USD
Change Today -0.0259 / -8.96%
Volume 3.6K
CRXM On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

taxus cardium pharmaceutical (CRXM) Snapshot

Open
$0.29
Previous Close
$0.29
Day High
$0.29
Day Low
$0.26
52 Week High
12/4/13 - $0.95
52 Week Low
10/17/14 - $0.22
Market Cap
3.2M
Average Volume 10 Days
17.8K
EPS TTM
$-0.65
Shares Outstanding
12.3M
EX-Date
10/24/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAXUS CARDIUM PHARMACEUTICAL (CRXM)

Related News

No related news articles were found.

taxus cardium pharmaceutical (CRXM) Related Businessweek News

No Related Businessweek News Found

taxus cardium pharmaceutical (CRXM) Details

Taxus Cardium Pharmaceuticals Group Inc. operates as a development-stage regenerative medicine biotechnology company. It focuses on developing regenerative therapeutics designed to support the activation and growth of microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and granulation tissue as a treatment for chronic non-healing wounds. The company provides Excellagen, a topical gel for wound healing of diabetic foot ulcers, and other dermal wounds, as well as serves as a biologics delivery platform in the United States. It develops Generx, a lead Phase III clinical study product candidate for the treatment of patients with Cardiac Microvascular Insufficiency due to advanced coronary artery disease. In addition, the company develops LifeAgain, a medical analytics and social media-driven enabled e-commerce platform that is focused on developing, marketing, and direct sale of life insurance programs and other insurance products for individuals with prostate cancer. Taxus Cardium Pharmaceuticals Group Inc. has strategic collaborations with Shanxi Taxus Pharmaceuticals Co., Ltd. for the development of advanced regenerative medicine therapeutics products; and Orbsen Therapeutics Ltd. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.

11 Employees
Last Reported Date: 04/15/14
Founded in 2003

taxus cardium pharmaceutical (CRXM) Top Compensated Officers

Co-Founder, Executive Chairman, Chief Executi...
Total Annual Compensation: $332.8K
Co-Founder, Chief Business Officer, Executive...
Total Annual Compensation: $309.0K
Chairman of Scientific Advisory Board and Chi...
Total Annual Compensation: $244.3K
Compensation as of Fiscal Year 2013.

taxus cardium pharmaceutical (CRXM) Key Developments

TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

TaxuCardium Pharmaceuticals Group Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced loss from operations of $956,325 compared to $1,856,351 for the same period a year ago. Net loss from continuing operations was $984,925 compared to $1,856,351 for the same period a year ago. Net loss was $984,925 compared to $2,117,548 for the same period a year ago. Net loss applicable to common stockholders was $984,925 compared to $2,350,559 for the same period a year ago. Net loss per share from continued operations, basic and diluted was $0.09 compared to $0.33 for the same period a year ago. Net loss per share, basic and diluted was $0.09 compared to $0.37 for the same period a year ago. Non-GAAP net loss was $983,807 compared to $2,117,548 for the same period a year ago. Non-GAAP net loss per common share, basic and diluted was $0.09 compared to $0.33 for the same period a year ago. For the six months, the company announced loss from operations of $2,375,747 compared to $3,831,604 for the same period a year ago. Net loss from continuing operations was $2,423,414 compared to $3,832,158 for the same period a year ago. Net loss was $2,423,414 compared to $4,379,903 for the same period a year ago. Net loss applicable to common stockholders was $2,423,414 compared to $4,612,914 for the same period a year ago. Net loss per share from continued operations, basic and diluted was $0.24 compared to $0.68 for the same period a year ago. Net loss per share, basic and diluted was $0.24 compared to $0.72 for the same period a year ago. Non-GAAP net loss was $1,916,131 compared to $4,339,153 for the same period a year ago. Non-GAAP net loss per common share, basic and diluted was $0.19 compared to $0.68 for the same period a year ago.

TaxuCardium Pharmaceuticals Group Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:20 PM

TaxuCardium Pharmaceuticals Group Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:20 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Christopher J. Reinhard, Co-Founder, Executive Chairman, Chief Executive Officer, President, Treasurer, Chief Executive Officer of Tissue Repair Company and President of Tissue Repair Company.

Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention

Taxus Cardium Pharmaceuticals Group Inc. will report at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(R) Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. Cardium will report on positive safety and statistically significant efficacy data from a randomized, multi-center, controlled study's primary registration endpoint of improvement in cardiac perfusion (blood flow) with Generx compared to the control group. Myocardial perfusion was measured by single-photon emission computed tomography (SPECT), a standard way of measuring blood flow at rest and during stress. Blood flow under stress was inadequate in all patients entering the study, as it is in millions of patients with heart disease worldwide. Patients were then randomized to receive the Generx product candidate or standard medical treatment for myocardial ischemia. Eight weeks following administration, the group of patients who received Generx were found to have significant improvements in myocardial blood flow under stress, as compared to the control group -- and the degree of improvement in Generx patients was of a magnitude that is similar to that observed following coronary interventions such as bypass surgery or angioplasty and stenting. The ASPIRE clinical study represents the fifth clinical study under the Generx gene therapy worldwide development program, which when completed will have evaluated over 780 patients at over 100 medical centers in the United States, Western Europe, South America, Canada and the Russian Federation, where the current ASPIRE study is being conducted. The Generx program is considered the large angiogenic cardiac gene therapy registration dossier in the world.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRXM:US $0.26 USD -0.0259

CRXM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRXM.
View Industry Companies
 

Industry Analysis

CRXM

Industry Average

Valuation CRXM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 163.4x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 147.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAXUS CARDIUM PHARMACEUTICAL, please visit www.cardiumthx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.